LipoCure

LipoCure Overview

LipoCure is developing a number of therapeutics utilizing proprietary liposome-based nano drugs with novel drug-loading capabilities and drug-release mechanisms. LipoCure's proprietary platform implements an approach that allows for remote drug loading into nano-liposomes and concomitant controlled release of the drugs at the targeted site. This technology is designed to produce an enhanced permeability and retention effect, a significantly improved therapeutic effect, and reduced side effects. It can be used in conjunction with several well-established drugs used for the treatment of rheumatoid arthritis, multiple sclerosis, and cancer. LipoCure's founder is professor Yechezkel Barenholz, the co-developer of Doxil.

Cumulative Funding Raised Over Time ($)

Latest News

Jun 4, 2018 · www.businesswire.com

Virpax Pharmaceuticals Licenses Liposome Drug Delivery Technology From LipoCure

Funding

Team Members

3

Employees: 1-10

Web & Social Links

Locations

Hadassah Ein Kerem Campus, Jerusalem, Israel

Photos & Videos

1 item(s)

LipoCure Internal

Recent Updates

No update log entries.

Note: Free-text notes visible in the original Finder "Internal" tab are not present in the imported profile data. Only the update audit log is available.

Admin Info